June 2018
Texas Biomed will focus itself on understanding the biology of infectious diseases and contribute to their eradication or management.
Trustees approve new vision for Texas Biomed

Texas Biomed is launching a 10-year strategic plan to position the Institute as the world's leader in infectious disease research. By bringing together the best minds and providing exceptional resources, we will advance the study of how people are impacted by infection. Our scientists can make great strides in diagnosing, preventing and curing disease. Texas Biomed is in a unique position to combat the growing worldwide threat of infectious diseases and protect the lives of our families, friends and the global community. Watch this video to see why we are embracing this bold vision.

Eusondia Arnett, Ph.D., and Larry Schlesinger, M.D., are two of the authors of this study.
Repurposing promising cancer drugs may lead to a new approach to treating TB

Promising experimental cancer chemotherapy drugs may help knock out another life-threatening disease: tuberculosis (TB). A new study published by scientists at Texas Biomedical Research Institute in San Antonio pinpoints a mechanism in regulating cell death called apoptosis that is a potential new target for helping to control the bacterial infection (Mycobacterium tuberculosis or M.tb) that causes the lung disease TB. This could speed up the time it takes to get a new treatment to patients with tuberculosis since some of these new agents are already being tested in humans.
Photo Courtesy healthcautions.com
SNPRC Helping Tackle Whooping Cough
The Southwest National Primate Research Center is embarking on a collaboration with other national institutions to test improvements to the current pertussis vaccine. Baboons are a good animal model for whooping cough as they mimic human symptoms of the disease, which has been on the rise despite the fact vaccines have been around since the 1940s. To learn more about our work in this area, listen to our podcast Who's Afraid of the Big Bad Cough?
Reporter Henry Ramos of KENS5 interviews Dr. Ricardo Carrion, Jr.
Ebola research garners attention with new outbreak in Africa
Scientists at Texas Biomed had several opportunities to educate the public about ongoing efforts to develop new therapies for Ebola. Stories aired on KENS5, KLRN-TV, and WOAI Radio. Researchers are helping test a promising experimental therapy for Ebola called ZMapp for Mapp Biopharmaceutical, Inc. Texas Biomed is performing pivotal studies that will transition ZMapp towards FDA licensure.
Listen: New Podcasts
Thanks to our Supporters!
Donor support for Texas Biomed has a long, fascinating history. One group, The Forum, is featured in a new podcast titled "Women Who Support Science."   Subscribe to our podcasts either through iTunes, Android, Stitcher, TuneIn or by email. Click here to enter your email address and you'll get a new episode in your inbox every two weeks.
Wendy Rigby
Media and Communications Specialist
8715 W. Military Dr., San Antonio, TX 78227